Twist Bioscience Corp (TWST) earnings date
Feb 5, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q1 FY2027
- Confidence
- 45% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-18
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 34 days, typically, give or take 5 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q4 FY2026 | Thu, Nov 12, 2026 | before open | 43 | 8-K |
| Q3 FY2026 | Mon, Aug 3, 2026 | before open | 34 | 8-K |
| Q2 FY2026 | Mon, May 4, 2026 | before open | 34 | 8-K |
| Q1 FY2026 | Mon, Feb 2, 2026 | before open | 33 | 8-K |
| Q4 FY2025 | Fri, Nov 14, 2025 | before open | 45 | 8-K |
| Q3 FY2025 | Mon, Aug 4, 2025 | before open | 35 | 8-K |
| Q2 FY2025 | Mon, May 5, 2025 | before open | 35 | 8-K |
| Q1 FY2025 | Mon, Feb 3, 2025 | before open | 34 | 8-K |
What they guided beta
| Q4 FY2026 | "Document Exhibit 99.1 Twist Bioscience Reports Fiscal Fourth Quarter and Full Year Fiscal 2026 Financial Results — Record revenue of $459.4 million in Fiscal 2026; Increase of 22% over $376.6 million in Fiscal 2025 — — Record revenue of $126.6 million in 4QFY26 ; Increase of approximately 28% over $99.0 million in 4QFY25 ; 15th consecutive quarter of sequential growth — — Gross margin of 52.4% in fiscal 2026 , Improvement of 1.7 margin points versus 50.7% in fiscal 2025 — — Fiscal 2027 revenue guidance of $550M-$560M, growth of 21% year over year at the midpoint — — First quarter fiscal 2027 " exhibit |
| Q4 FY2026 | "Fiscal 2027 Financial Guidance The following statements are based on Twist’s current expectations for fiscal 2027." exhibit |
| Q4 FY2026 | "For the full fiscal year 2027, Twist expects:" exhibit |
| Q4 FY2026 | "Initial full year revenue guidance assumes $100 million in revenue for AI drug discovery and sequential growth across both DNA Synthesis and Protein Solutions and NGS Applications" exhibit |
| Q4 FY2026 | "Capital expenditures of approximately $75 million as part of our two-year investment plan, excluding landlord-funded tenant improvements For the first quarter of fiscal 2027, Twist expects:" exhibit |
| Q3 FY2026 | "Document Exhibit 99.1 Twist Bioscience Reports Fiscal Third Quarter 2026 Financial Results — Record revenue of $118.4 million in 3QFY26 ; Increase of more than 23% over $96.1 million in 3QFY25; 14th consecutive quarter of sequential growth — — Gross margin of 52.8% in 3QFY26, sequential increase of 120 basis points — — FY 2026 Revenue guidance raised to $456-$457M, an increase of $12M at the midpoint; Reiterating Q4 FY26 Adj EBITDA breakeven — SOUTH SAN FRANCISCO, Calif. -- (August 3, 2026) — Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today report" exhibit |
| Q3 FY2026 | ""We continued our pattern of strong growth, reporting our fourteenth consecutive quarter of growth and exceeding guidance with revenue for the third quarter of fiscal 2026 of $118.4 million, growth of more than 23% compared to the third quarter of fiscal 2025," said Emily M." exhibit |
| Q3 FY2026 | "Fiscal 2026 Financial Guidance The following statements are based on Twist’s current expectations for fiscal 2026." exhibit |
| Q3 FY2026 | "For the full fiscal year 2026, Twist expects :" exhibit |
| Q3 FY2026 | "A reconciliation of adjusted EBITDA for the fourth quarter of fiscal 2026 to a corresponding GAAP financial guidance measure is not available on a forward-looking basis because the Company does not provide guidance on GAAP net (loss) income and is not able to present the various reconciling cash and non-cash items between GAAP net (loss) income and adjusted EBITDA without unreasonable effort." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/TWST
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/TWST
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/TWST/"><img src="https://veritasdata.dev/embed/TWST.svg" alt="TWST earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/TWST/)
Script
<script async src="https://veritasdata.dev/embed/TWST.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/TWST"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.